Blackstone backs Ferring candidate with $400 million

25 November 2019

Privately-held Swiss drugmaker Ferring Pharmaceuticals has launched a new gene therapy company, FerGene, together with Blackstone Life Sciences.

A joint investment of $570 million will be used to support lead candidate nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy in late stage development for certain people with non-muscle invasive bladder cancer (NMIBC).

Blackstone will invest $400 million and Ferring will invest up to $170 million in the joint venture.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK